Bicycle Therapeutics Valuation
| BCYC Stock | USD 8.37 0.06 0.72% |
At this time, the firm appears to be overvalued. Bicycle Therapeutics shows a prevailing Real Value of $6.93 per share. The current price of the firm is $8.37. Our model approximates the value of Bicycle Therapeutics from analyzing the firm fundamentals such as return on equity of -0.37, and Operating Margin of (7.04) % as well as examining its technical indicators and probability of bankruptcy. Key fundamental drivers impacting Bicycle Therapeutics' valuation include:
Price Book 0.783 | Enterprise Value | Enterprise Value Ebitda (2.14) | Price Sales 22.3739 | Enterprise Value Revenue 21.2178 |
Overvalued
Today
Please note that Bicycle Therapeutics' price fluctuation is slightly risky at this time. Calculation of the real value of Bicycle Therapeutics is based on 3 months time horizon. Increasing Bicycle Therapeutics' time horizon generally increases the accuracy of value calculation and significantly improves the predictive power of the methodology used.
Since Bicycle Therapeutics is currently traded on the exchange, buyers and sellers on that exchange determine the market value of Bicycle Stock. However, Bicycle Therapeutics' intrinsic value may or may not be the same as its current market price, in which case there is an opportunity to profit from the mispricing, assuming the market price will eventually merge with its intrinsic value. | Historical | Market 8.37 | Real 6.93 | Target 26.27 | Hype 8.37 | Naive 8.93 |
The real value of Bicycle Stock, also known as its intrinsic value, is the underlying worth of Bicycle Therapeutics Company, which is reflected in its stock price. It is based on Bicycle Therapeutics' financial performance, growth prospects, management team, or industry conditions. The intrinsic value of Bicycle Therapeutics' stock can be calculated using various methods such as discounted cash flow analysis, price-to-earnings ratio, or price-to-book ratio. That value may differ from its current market price, which is determined by supply and demand factors such as investor sentiment, market trends, or news.
Estimating the potential upside or downside of Bicycle Therapeutics helps investors to forecast how Bicycle stock's addition to their portfolios will impact the overall performance. We also use other valuation drivers to help us estimate the true value of Bicycle Therapeutics more accurately as focusing exclusively on Bicycle Therapeutics' fundamentals will not take into account other important factors: Traditionally, analysts and sophisticated investors use multiple methods for valuing a cash-flow-generating entity or its stock. For example, some money managers use Bicycle Therapeutics' intrinsic value based on its ongoing forecasts of Bicycle Therapeutics' financial statements. In contrast, other private, professional wealth advisors use a multiplier approach by looking to relative value analysis against Bicycle Therapeutics' closest peers. If more than one evaluation category is relevant for Bicycle Therapeutics we suggest using both methods to arrive at a better estimate.
Bicycle Therapeutics Cash |
|
Bicycle Valuation Trend
Comparing Bicycle Therapeutics' enterprise value against its market capitalization is a good way to estimate the value of Bicycle Therapeutics uage its performance over time. This information may sometimes be enough for investors to make reasonable market timing decisions.
Bicycle Therapeutics Total Value Analysis
Bicycle Therapeutics is currently anticipated to have valuation of (204.99 M) with market capitalization of 575.5 M, debt of 9.49 M, and cash on hands of 372.77 M. The negative valuation of Bicycle Therapeutics may imply that the market is not capable to price the future growth of the company or it is pricing it at zero value. It may also suggest that takeover valuation may not have captured all of the outstanding financial obligations of the company both on and off balance sheet. Investors should vigilantly validate all of the Bicycle Therapeutics fundamentals.| Takeover Price | Market Cap | Debt Obligations | Cash |
(204.99 M) | 575.5 M | 9.49 M | 372.77 M |
Bicycle Therapeutics Investor Information
About 93.0% of the company shares are held by institutions such as insurance companies. The company has price-to-book (P/B) ratio of 0.78. Some equities with similar Price to Book (P/B) outperform the market in the long run. Bicycle Therapeutics recorded a loss per share of 3.18. The entity had not issued any dividends in recent years. Based on the key indicators related to Bicycle Therapeutics' liquidity, profitability, solvency, and operating efficiency, Bicycle Therapeutics is not in a good financial situation at this time. It has a very high odds of going through financial crisis in August.Bicycle Therapeutics Asset Utilization
The asset utilization indicator refers to the revenue earned for every dollar of assets a company currently reports. Bicycle Therapeutics has an asset utilization ratio of 3.69 percent. This indicates that the Company is making $0.0369 for each dollar of assets. An increasing asset utilization means that Bicycle Therapeutics is more efficient with each dollar of assets it utilizes for everyday operations.Bicycle Therapeutics Ownership Allocation
Bicycle Therapeutics holds a total of 47.76 Million outstanding shares. The majority of Bicycle Therapeutics outstanding shares are owned by other corporate entities. These outside corporations are usually referred to as non-private investors looking to acquire positions in Bicycle Therapeutics to benefit from reduced commissions. Consequently, institutional investors are subject to a different set of regulations than regular investors in Bicycle Therapeutics. Please pay attention to any change in the institutional holdings of Bicycle Therapeutics as this could imply that something significant has changed or is about to change at the company. Please note that no matter how many assets the company secures, if the real value of the firm is less than the current market value, you may not be able to make money on it.Bicycle Therapeutics Profitability Analysis
The company reported the previous year's revenue of 35.27 M. Net Loss for the year was (169.03 M) with loss before overhead, payroll, taxes, and interest of (171.57 M).Please note that valuation analysis is one of the essential comprehensive assessments in business. It evaluates Bicycle Therapeutics' worth, which you can determine by considering its current assets, liabilities and future cash flows. The investors' valuation analysis is an important metric that will give you a perspective on different companies. It helps you know the worth of the potential investment in Bicycle Therapeutics and how it compares across the competition.
About Bicycle Therapeutics Valuation
The stock valuation mechanism determines Bicycle Therapeutics' current worth on a weekly basis. Our valuation model uses a comparative analysis of Bicycle Therapeutics. We calculate exposure to Bicycle Therapeutics's market risk, different technical and fundamental indicators, and relevant financial multiples and ratios and then compare them to those of Bicycle Therapeutics's related companies.| Last Reported | Projected for Next Year | ||
| Gross Profit | 28.1 M | 29.5 M | |
| Pretax Profit Margin | (4.93) | (5.17) | |
| Operating Profit Margin | (5.95) | (6.25) | |
| Net Loss | (4.79) | (5.03) | |
| Gross Profit Margin | 0.80 | 0.84 |
Bicycle Therapeutics Growth Indicators
Growth stocks usually refer to those companies expected to grow sales and earnings faster than the market average. Growth stocks typically don't pay dividends, often look expensive, and usually trading at a high P/E ratio. Nevertheless, such valuations could be relatively cheap if the company continues to grow, which will drive the share price up. However, since most investors are paying a high price for a growth stock, based on expectations, if those expectations are not fully realized, growth stocks can see dramatic declines.
| Common Stock Shares Outstanding | 58.2 M |
Bicycle Therapeutics Current Valuation Indicators
Valuation refers to the process of determining the present value of Bicycle Therapeutics and all of its assets. It can be calculated using a number of techniques. As many analysts who try to value Bicycle we look at many different elements of the entity such as Bicycle's management, its prospective future earnings, the current market value of the company's assets, as well as its capital structure formation.
Valuations are an essential part of business, for companies themselves, but also for investors. For companies, such as Bicycle Therapeutics, valuations can help measure their progress and success and can help them track their performance in the market compared to others. In addition, investors can use Bicycle Therapeutics' valuations to help determine the worth of potential investments. They can do this by using data and information made public by a company. Regardless of who the valuation is for, it essentially describes Bicycle Therapeutics' worth.Complementary Tools for Bicycle Stock analysis
When running Bicycle Therapeutics' price analysis, check to measure Bicycle Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Bicycle Therapeutics is operating at the current time. Most of Bicycle Therapeutics' value examination focuses on studying past and present price action to predict the probability of Bicycle Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Bicycle Therapeutics' price. Additionally, you may evaluate how the addition of Bicycle Therapeutics to your portfolios can decrease your overall portfolio volatility.
| Earnings Calls Check upcoming earnings announcements updated hourly across public exchanges | |
| Options Analysis Analyze and evaluate options and option chains as a potential hedge for your portfolios | |
| Instant Ratings Determine any equity ratings based on digital recommendations. Macroaxis instant equity ratings are based on combination of fundamental analysis and risk-adjusted market performance | |
| Piotroski F Score Get Piotroski F Score based on the binary analysis strategy of nine different fundamentals |